The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
The value of patient reporting to the pharmacovigilance system: a systematic review
Open accessAbstract
Aims: Current trends in pharmacovigilance systems are veering towards patient involvement in spontaneous reporting of adverse drug reactions (ADRs). The aim of the current systematic review was to identify what is known and what remains unknown with respect to patient reporting to pharmacovigilance systems. Methods: A systematic literature search was conducted in PubMed, CINAHL, Journals@Ovid and the Cochrane Library. Studies were included if they contained: (i) reviews about patient reporting; (ii) evaluation of patient reports to national or supranational pharmacovigilance authorities; (iii) a comparison between patient and healthcare professional (HCP) reports submitted to pharmacovigilance authorities; and (iv) surveys of patient experiences, opinions and awareness about reporting ADRs. The methodological quality of the studies was assessed according to principles of Grading of Recommendations, Assessment, Development and Evaluations (GRADE). Results: A total of thirty four studies were included. Five of the studies were reviews (two of which systematic reviews), fourteen retrospective observational studies, nine surveys and six applied mixed research methods. Patient reporting has the advantages of bringing novel information about ADRs. It provides a more detailed description of ADRs, and reports about different drugs and system organ classes when compared with HCP reporting. In addition, patients describe the severity and impact of ADRs on daily life, complementing information derived from HCPs. Patient reporting is relatively rare in most countries. Conclusions: Patient reporting adds new information, and perspective about ADRs in a way otherwise unavailable. This can contribute to better decision‐making processes in regulatory activities. The present review identified gaps in knowledge that should be addressed to improve our understanding of the full potential and drawbacks of patient reporting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PRISMA-P Group, Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., & Stewart, L. A. (2015) · Systematic Reviews · doi:10.1186/2046-4053-4-1 · Cited by 26,223
Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies
Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998) · JAMA · doi:10.1001/jama.279.15.1200 · Cited by 4,807
Under-Reporting of Adverse Drug Reactions: A Systematic Review
Hazell, L., & Shakir, S. A. W. (2006) · Drug Safety · doi:10.2165/00002018-200629050-00003 · Cited by 1,931
From Randomized Controlled Trials to Observational Studies
Silverman, S. L. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.030 · Cited by 358
Avery, A., Anderson, C., Bond, C., Fortnum, H., Gifford, A., Hannaford, P., Hazell, L., Krska, J., Lee, A., McLernon, D., et al. (2011) · Health Technology Assessment · doi:10.3310/hta15200 · Cited by 331
Blenkinsopp, A., Wilkie, P., Wang, M., & Routledge, P. A. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02746.x · Cited by 302
Pharmacovigilance: methods, recent developments and future perspectives
Härmark, L., & van Grootheest, A. C. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0475-9 · Cited by 289
Pal, S. N., Duncombe, C., Falzon, D., & Olsson, S. (2013) · Drug Safety · doi:10.1007/s40264-012-0014-6 · Cited by 233
Adverse Drug Reaction Reporting by Patients in the Netherlands: Three Years of Experience
de Langen, J., van Hunsel, F., Passier, A., de Jong-van den Berg, L., & van Grootheest, K. (2008) · Drug Safety · doi:10.2165/00002018-200831060-00006 · Cited by 177
Experiences with Adverse Drug Reaction Reporting by Patients
van Hunsel, F. P. A. M., Härmark, L., Pal, S. N., Olsson, S., & van Grootheest, K. (2011) · Drug Safety · doi:10.2165/11594320-000000000-00000 · Cited by 146
Pharmacovigilance in Perspective
Meyboom, R. H. B., Egberts, T. C. G., Gribnau, F. W. J., & Hekster, Y. A. (1999) · Drug Safety · doi:10.2165/00002018-199921060-00001 · Cited by 144
Consumer Reporting of Adverse Drug Reactions
Aagaard, L., Nielsen, L. H., & Hansen, E. H. (2009) · Drug Safety · doi:10.2165/11316680-000000000-00000 · Cited by 113
Adverse Drug Reaction Reporting in the UK
McLernon, D. J., Bond, C. M., Hannaford, P. C., Watson, M. C., Lee, A. J., Hazell, L., & Avery, A. J. (2010) · Drug Safety · doi:10.2165/11536510-000000000-00000 · Cited by 105
Adverse Drug Reaction Reporting by Patients: An Overview of Fifty Countries
Margraff, F., & Bertram, D. (2014) · Drug Safety · doi:10.1007/s40264-014-0162-y · Cited by 94
Anderson, C., Krska, J., Murphy, E., & Avery, A. J. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03990.x · Cited by 93
van Hunsel, F. P. A. M., Passier, A., & van Grootheest, K. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03400.x · Cited by 87
Motives for reporting adverse drug reactions by patient-reporters in the Netherlands
van Hunsel, F. P. A. M., der Welle, C. M. C., Passier, A., van Puijenbroek, E., & van Grootheest, K. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-010-0865-7 · Cited by 87
Rolfes, L., van Hunsel, F. P. A. M., Wilkes, S., van Grootheest, K., & van Puijenbroek, E. (2014) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3687 · Cited by 85
ADR Reporting by the General Public: Lessons Learnt from the Dutch and Swedish Systems
Härmark, L., van Hunsel, F. P. A. M., & Grundmark, B. (2015) · Drug Safety · doi:10.1007/s40264-015-0264-1 · Cited by 76
Evaluating Social Media Networks in Medicines Safety Surveillance: Two Case Studies
Coloma, P. M., Becker, B. F. H., Sturkenboom, M., van Mulligen, E. M., & Kors, J. A. (2015) · Drug Safety · doi:10.1007/s40264-015-0333-5 · Cited by 61
Adverse Drug Reactions of Spontaneous Reports in Shanghai Pediatric Population
Li, H., Guo, X., Ye, X., Jiang, H. F., Du, W., Xu, J., Zhang, X., & He, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089829 · Cited by 57
What can we learn from parents about enhancing participation in pharmacovigilance?
Arnott, J., Hesselgreaves, H., Nunn, A. J., Peak, M., Pirmohamed, M., Smyth, R. L., Turner, M. A., & Young, B. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04441.x · Cited by 40
A qualitative study to explore how patients identify and assess symptoms as adverse drug reactions
Chaipichit, N., Krska, J., Pratipanawatr, T., Uchaipichat, V., & Jarernsiripornkul, N. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1653-6 · Cited by 36
Adverse drug reactions reported by consumers for nervous system medications in Europe 2007 to 2011
Aagaard, L., & Hansen, E. H. (2013) · BMC Pharmacology and Toxicology · doi:10.1186/2050-6511-14-30 · Cited by 33
Durrieu, G., Palmaro, A., Pourcel, L., Caillet, C., Faucher, A., Jacquet, A., Ouaret, S., Pérault‐Pochat, M. C., Kreft-Jaïs, C., Castot, A., et al. (2012) · Drug Safety · doi:10.1007/bf03261980 · Cited by 32
van Hunsel, F. P. A. M., van Puijenbroek, E., van den Berg, L. D. J., & van Grootheest, K. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1865 · Cited by 32
Web-Based Patient-Reported Outcomes in Drug Safety and Risk Management
Banerjee, A. K., & Ingate, S. (2012) · Drug Safety · doi:10.2165/11632390-000000000-00000 · Cited by 32
Sources of information used by regulatory agencies on the generation of drug safety alerts
Alves, C., Macedo, A. F., & Marques, F. B. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1564-y · Cited by 30
A plea for a more epidemiological and patient-oriented pharmacovigilance
Scurti, V., Romero, M., & Tognoni, G. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1096-2 · Cited by 26
Intensive monitoring of duloxetine: results of a web-based intensive monitoring study
Härmark, L., van Puijenbroek, E., & van Grootheest, K. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1313-7 · Cited by 25
Gathering and Exploring Scientific Knowledge in Pharmacovigilance
Lopes, P. H. D. M. B., Nunes, T., Campos, D., Furlong, L. I., Bauer‐Mehren, A., Sanz, F., Carrascosa, M. C., Mestres, J., Kors, J. A., Singh, B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083016 · Cited by 23
Pharmacovigilance: empowering healthcare professionals and patients
Steurbaut, S., & Hanssens, Y. I. (2014) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-014-0004-0 · Cited by 21
Adverse drug reactions in children reported by European consumers from 2007 to 2011
Aagaard, L., & Hansen, E. H. (2013) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-013-9874-9 · Cited by 15
Oosterhuis, I., Härmark, L., & van Puijenbroek, E. (2014) · Drug Safety · doi:10.1007/s40264-014-0166-7 · Cited by 9
Cited by
Raschi, E., Mazzarella, A., Antonazzo, I. C., Bendinelli, N., Forcesi, E., Tuccori, M., Moretti, U., Poluzzi, E., & De Ponti, F. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00632-w · Cited by 101
Anjum, R. L., Price, C., & Rocca, E. (2025) · Social Epistemology · doi:10.1080/02691728.2024.2400079 · Cited by 3
Metadata
- Authors
- Inácio, P., Cavaco, A., & Airaksinen, M.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2016-10-12
- Volume
- 83
- Issue
- 2
- Pages
- 227-246
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W2516356692
- Cited by
- 269
- References
- 34
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.